Payment overview · 2025
General Payments
$236.88
14 reported records · 8 companies
Healthcare provider profile · identity verified
Teresa Kay Johnson, MD
Allopathic & Osteopathic Physicians|Family Medicine · IDAHO FALLS, ID · NPI 1285642322
Verified facts
What the public records show
CMS Open Payments records show Teresa Kay Johnson, MD received $236.88 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.76 | 19.7% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $44.22 | 18.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.80 | 18.1% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $34.72 | 14.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.80 | 8.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.88 | 7.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.56 | 7.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.14 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $236.88 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $46.76 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $46.76 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.80 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $34.72 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $30.18 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $28.12 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 96 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
96 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 426 | 105 |
| Atorvastatin Calcium | Atorvastatin Calcium | 281 | 74 |
| Valsartan | Valsartan | 236 | 57 |
| Gabapentin | Gabapentin | 217 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 203 | 30 |
| Omeprazole | Omeprazole | 172 | 44 |
| Metformin Hcl Er | Metformin Hcl | 168 | 38 |
| Lisinopril | Lisinopril | 161 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 158 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 153 | 35 |
| Amlodipine Besylate | Amlodipine Besylate | 146 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 144 | 28 |
| Bupropion Xl | Bupropion Hcl | 119 | 24 |
| Simvastatin | Simvastatin | 110 | 30 |
| Alendronate Sodium | Alendronate Sodium | 109 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 105 | 24 |
| Famotidine | Famotidine | 99 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 19 |
| Eliquis | Apixaban | 96 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 25 |
| Trazodone Hcl | Trazodone Hcl | 92 | 21 |
| Metformin Hcl | Metformin Hcl | 91 | 26 |
| Celecoxib | Celecoxib | 87 | 24 |
| Prednisone | Prednisone | 85 | 29 |
| Tramadol Hcl | Tramadol Hcl | 80 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 26 |
| Potassium Chloride | Potassium Chloride | 77 | 23 |
| Montelukast Sodium | Montelukast Sodium | 76 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 23 |
| Estradiol | Estradiol | 72 | 20 |
| Lorazepam | Lorazepam | 72 | 17 |
| Furosemide | Furosemide | 71 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 65 | suppressed |
| Clonazepam | Clonazepam | 63 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | suppressed |
| Allopurinol | Allopurinol | 58 | 16 |
| Methocarbamol | Methocarbamol | 57 | suppressed |
| Baclofen | Baclofen | 56 | suppressed |
| Losartan Potassium | Losartan Potassium | 56 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 55 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | suppressed |
| Nystatin | Nystatin | 53 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 11 |
| Spironolactone | Spironolactone | 46 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 45 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 32 |
| Colestipol Hcl | Colestipol Hcl | 43 | suppressed |
| Meloxicam | Meloxicam | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 13 |
| Memantine Hcl | Memantine Hcl | 39 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 36 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 34 | suppressed |
| Ozempic | Semaglutide | 34 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 12 |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 19 |
| Fentanyl | Fentanyl | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Sotalol | Sotalol Hcl | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Carvedilol | Carvedilol | 22 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 22 | suppressed |
| Zaleplon | Zaleplon | 22 | 11 |
| Diazepam | Diazepam | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Armour Thyroid | Thyroid,pork | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 12 |
| Acyclovir | Acyclovir | 19 | suppressed |
| Ciclopirox | Ciclopirox | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $236.88 · 14 records | ABBVIE INC. | CAPLYTA, ELIQUIS, EVENITY, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, UBRELVY, VOQUEZNA, YUPELRI, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error